Cervical Cancer :: GSK’s Cervarix receives positive opinion in Europe for cervical cancer
GlaxoSmithKline (GSK) announced that its cervical cancer candidate vaccine received a positive opinion from the European Committee for Human Medicinal Products (CHMP) for the prevention of precancerous lesions (high grade cervical intraepithelial neoplasia – CIN grades 2 and 3) and cervical cancer causally related to human papillomavirus types 16 and 18.